Australia's most trusted
source of pharma news
Thursday, 18 September 2025
Posted 17 September 2025 AM
CSL has signed a development agreement for a potential first-in-class blood drug, and nabbed the option to purchase the whole company if it is especially pleased with the trial results.
Privately-held Dutch company VarmX signed the deal with CSL for VMX-C001, a potential first-in-class recombinant Factor X protein administered as a rapid single-dose, intended to counter dangerous effects of patients taking FXa inhibitors as chronic anticoagulation therapy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.